{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"93.6","upperLimit":"96.9","value":"95.22"},{"groupId":"OG001","lowerLimit":"92.1","upperLimit":"95.8","value":"93.96"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"928"},{"groupId":"OG001","value":"929"}],"units":"Participants"}],"description":"Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive standard consolidation therapy (vincristine sulfate, mercaptopurine and methotrexate. Patients with Down syndrome (DS) receive leucovorin calcium), standard interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine and methotrexate. Patients with DS receive leucovorin calcium), and standard delayed intensification (DI) therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and methotrexate. Patients with DS receive dexamethasone, leucovorin calcium), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.\n\ndoxorubicin hydrochloride: Given IV or IT\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nleucovorin calcium: Given PO\n\nmercaptopurine: Given PO\n\ncyclophosphamide: Given IV\n\nthioguanine: Given PO\n\nvincristine sulfate: Given IV","id":"OG000","title":"SR-low ALL, Arm I-combination Chemotherapy"},{"description":"Patients receive experimental consolidation therapy (vincristine sulfate, mercaptopurine, MTX, leucovorin calcium and pegaspargase), experimental interim maintenance therapy (vincristine sulfate, dexamethasone, mercaptopurine, MTX and pegaspargase), and standard DI therapy (vincristine sulfate, dexamethasone, doxorubicin hydrochloride, pegaspargase, cyclophosphamide, cytarabine, thioguanine and MTX), followed by maintenance therapy. Therapies are given by mouth, injection, and infusion for up to 2 or 3 years.\n\ndoxorubicin hydrochloride: Given IV or IT\n\ncytarabine: Given IV or SC\n\ndexamethasone: Given IV or PO\n\npegaspargase: Given IM\n\nmethotrexate: Given IM or IT\n\nleucovorin calcium: Given PO\n\nmercaptopurine: Given PO\n\ncyclophosphamide: Given IV\n\nthioguanine: Given PO\n\nvincristine sulfate: Given IV","id":"OG001","title":"SR-low ALL, Arm II-combination Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Only eligible patients are included in the analysis.","reportingStatus":"POSTED","timeFrame":"6 years","title":"Event-free Survival (EFS) for SR-Low Patients","type":"PRIMARY","unitOfMeasure":"Percent probability"}